deltatrials

Metastatic malignant neoplasm in the brain Trials in Ann Arbor, United States

Conditions / Metastatic malignant neoplasm in the brain / Ann Arbor, United States

Metastatic malignant neoplasm in the brain has been the subject of sustained clinical investigation across multiple research sites.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT04114981 Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease ACTIVE_NOT_RECRUITING
NCT02360215 Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases COMPLETED PHASE3
NCT03994796 Genetic Testing in Guiding Treatment for Patients With Brain Metastases SUSPENDED PHASE2
NCT02595905 Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases COMPLETED PHASE2
NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain RECRUITING PHASE3
NCT04804644 Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability RECRUITING
NCT05438212 Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases ACTIVE_NOT_RECRUITING PHASE3
NCT01622868 Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer COMPLETED PHASE2
NCT04114981 Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease ACTIVE_NOT_RECRUITING
NCT03418961 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity RECRUITING PHASE3

Related Pages